EGb 761 in the Syndrome of MCI With Concomitant CVD
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age45-85
SponsorNational Neuroscience Institute
About this trial
EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.
Eligibility criteria
Qualifiers
Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS criteria
Patients who have a Global Clinical Dementia Rating Score of 0.5
Patients aged 45 to 85 years at study entry
Patients who are literate and able to complete the cognitive evaluations in the opinion of the investigators
Disqualifiers
Participants should not be receiving antidepressants, antipsychotics, benzodiazepines, acetylcholinesterase inhibitors or NMDA antagonists during the study. Additionally, contraindications for EGb 761 as given in the local prescribing information/Summary of Product Characteristics (SmPC) should be observed.
Trial design
Treatments tested in this trial
- Tebonin Forte
Treatment groups
134 Participants
are divided into 2 treatment groupsSponsors and collaborators
National Neuroscience Institute
Lead sponsor
Dr. Willmar Schwabe GmbH & Co. KG
Collaborator
Source ClinicalTrials.gov